The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.30465. At the end of 2023 the company had a P/S ratio of 5.04.
Year | P/S ratio | Change |
---|---|---|
2023 | 5.04 | 2.32% |
2022 | 4.92 | 15.58% |
2021 | 4.26 | 3.14% |
2020 | 4.13 | 4.92% |
2019 | 3.94 | -5.43% |
2018 | 4.16 | -23.93% |
2017 | 5.47 | 37.85% |
2016 | 3.97 | -4.86% |
2015 | 4.17 | -20.04% |
2014 | 5.22 | 16.95% |
2013 | 4.46 | 51.93% |
2012 | 2.94 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.73 | -48.61% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.3 | 282.28% | ๐บ๐ธ USA |
Amgen AMGN | 5.70 | 7.43% | ๐บ๐ธ USA |
Biogen BIIB | 3.34 | -37.11% | ๐บ๐ธ USA |
Gilead Sciences GILD | 3.01 | -43.18% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 1.95 | -63.16% | ๐บ๐ธ USA |
AstraZeneca AZN | 4.96 | -6.47% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | 2.30 | -56.67% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | 7.20 | 35.64% | ๐บ๐ธ USA |